Effectiveness of Ziprasidone for Patients With Schizophrenia
Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder
Sponsor: Pfizer
This PHASE4 trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- Soonchunhyang University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Ansan, South Korea
- • Bucheon-si, South Korea
- • Incheon, South Korea
- • Seoul, South Korea